-
1
-
-
0033524159
-
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
-
ATTRACT Study Group
-
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-1939.
-
(1999)
Lancet
, vol.354
, pp. 1932-1939
-
-
Maini, R.1
St Clair, E.W.2
Breedveld, F.3
Furst, D.4
Kalden, J.5
Weisman, M.6
-
2
-
-
0034735842
-
Infliximab and methotrexate in the treatment of rheumatoid arthritis
-
Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
-
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-1602
-
(2000)
N Engl J Med
, vol.343
, pp. 1594-1602
-
-
Lipsky, P.E.1
Van Der Heijde, D.M.2
St Clair, E.W.3
Furst, D.E.4
Breedveld, F.C.5
Kalden, J.R.6
-
3
-
-
11144354315
-
Sustained Improvement over Two Years in Physical Function, Structural Damage, and Signs and Symptoms among Patients with Rheumatoid Arthritis Treated with and Methotrexate
-
DOI 10.1002/art.20159
-
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-1065 (Pubitemid 38480815)
-
(2004)
Arthritis and Rheumatism
, vol.50
, Issue.4
, pp. 1051-1065
-
-
Maini, R.N.1
Breedveld, F.C.2
Kalden, J.R.3
Smolen, J.S.4
Furst, D.5
Weisman, M.H.6
St Clair, E.W.7
Keenan, G.F.8
Van Der Heijde, D.9
Marsters, P.A.10
Lipsky, P.E.11
-
4
-
-
8444239359
-
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
-
DOI 10.1002/art.20568
-
St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-3443 (Pubitemid 39488667)
-
(2004)
Arthritis and Rheumatism
, vol.50
, Issue.11
, pp. 3432-3443
-
-
St.clair, E.W.1
Van Der Heijde, D.M.F.M.2
Smolen, J.S.3
Maini, R.N.4
Bathon, J.M.5
Emery, P.6
Keystone, E.7
Schiff, M.8
Kalden, J.R.9
Wang, B.10
Dewoody, K.11
Weiss, R.12
Baker, D.13
-
5
-
-
0037231533
-
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
-
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2004;48:35-45.
-
(2004)
Arthritis Rheum
, vol.48
, pp. 35-45
-
-
Weinblatt, M.E.1
Keystone, E.C.2
Furst, D.E.3
Moreland, L.W.4
Weisman, M.H.5
Birbara, C.A.6
-
6
-
-
0348109372
-
Adalimumab, a Fully Human Anti-Tumor Necrosis Factor-alpha Monoclonal Antibody, and Concomitant Standard Antirheumatic Therapy for the Treatment of Rheumatoid Arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)
-
Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-2571 (Pubitemid 37549331)
-
(2003)
Journal of Rheumatology
, vol.30
, Issue.12
, pp. 2563-2571
-
-
Furst, D.E.1
Schiff, M.H.2
Fleischmann, R.M.3
Strand, V.4
Birbara, C.A.5
Compagnone, D.6
Fischkoff, S.A.7
Chartash, E.K.8
-
7
-
-
2342658406
-
Radiographic, Clinical, and Functional Outcomes of Treatment with Adalimumab (a Human Anti-Tumor Necrosis Factor Monoclonal Antibody) in Patients with Active Rheumatoid Arthritis Receiving Concomitant Methotrexate Therapy: A Randomized, Placebo-Controlled, 52-Week Trial
-
DOI 10.1002/art.20217
-
Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-1411 (Pubitemid 38608061)
-
(2004)
Arthritis and Rheumatism
, vol.50
, Issue.5
, pp. 1400-1411
-
-
Keystone, E.C.1
Kavanaugh, A.F.2
Sharp, J.T.3
Tannenbaum, H.4
Hua, Y.5
Teoh, L.S.6
Fischkoff, S.A.7
Chartash, E.K.8
-
8
-
-
0033574147
-
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
-
Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-486
-
(1999)
Ann Intern Med
, vol.130
, pp. 478-486
-
-
Moreland, L.W.1
Schiff, M.H.2
Baumgartner, S.W.3
Tindall, E.A.4
Fleischmann, R.M.5
Bulpitt, K.J.6
-
9
-
-
0034735827
-
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
-
DOI 10.1056/NEJM200011303432201
-
Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593 (Pubitemid 32162981)
-
(2000)
New England Journal of Medicine
, vol.343
, Issue.22
, pp. 1586-1593
-
-
Bathon, J.M.1
Martin, R.W.2
Fleischmann, R.M.3
Tesser, J.R.4
Schiff, M.H.5
Keystone, E.C.6
Genovese, M.C.7
Wasko, M.C.8
Moreland, L.W.9
Weaver, A.L.10
Markenson, J.11
Finck, B.K.12
-
10
-
-
10744223002
-
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial
-
DOI 10.1016/S0140-6736(04)15640-7, PII S0140673604156407
-
Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-681 (Pubitemid 38296553)
-
(2004)
Lancet
, vol.363
, Issue.9410
, pp. 675-681
-
-
Klareskog, L.1
Van Der Heijde, D.2
De Jager, J.P.3
Gough, A.4
Kalden, J.5
Malaise, M.6
Martin Mola, E.7
Pavelka, K.8
Sany, J.9
Settas, L.10
Wajdula, J.11
Pedersen, R.12
Fatenejad, S.13
Sanda, M.14
-
11
-
-
0031660364
-
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
-
DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W
-
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-1563 (Pubitemid 28459913)
-
(1998)
Arthritis and Rheumatism
, vol.41
, Issue.9
, pp. 1552-1563
-
-
Maini, R.N.1
Breedveld, F.C.2
Kalden, J.R.3
Smolen, J.S.4
Davis, D.5
Macfarlane, J.D.6
Antoni, C.7
Leeb, B.8
Elliott, M.J.9
Woody, J.N.10
Schaible, T.F.11
Feldmann, M.12
-
12
-
-
31044442965
-
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
-
DOI 10.1002/art.21519
-
Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
-
(2006)
Arthritis and Rheumatism
, vol.54
, Issue.1
, pp. 26-37
-
-
Breedveld, F.C.1
Weisman, M.H.2
Kavanaugh, A.F.3
Cohen, S.B.4
Pavelka, K.5
Van Vollenhoven, R.6
Sharp, J.7
Perez, J.L.8
Spencer-Green, G.T.9
-
13
-
-
65549141955
-
-
Thousand Oaks, CA: Immunex Corporation
-
ENBREL (package insert). Thousand Oaks, CA: Immunex Corporation, 2008.
-
(2008)
ENBREL (Package Insert)
-
-
-
14
-
-
64249086014
-
-
North Chicago, IL: Abbott Laboratories
-
HUMIRA (package insert). North Chicago, IL: Abbott Laboratories, 2008.
-
(2008)
HUMIRA (Package Insert)
-
-
-
15
-
-
0003547850
-
-
Malvern, PA: Centocor, Inc
-
REMICADE (package insert). Malvern, PA: Centocor, Inc, 2007.
-
(2007)
REMICADE (Package Insert)
-
-
-
16
-
-
42449095670
-
Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for TNF-alpha
-
EULAR abstract THU0088
-
Shealy D, Cai A, Lacy E, Nesspor T, Staquet K, Johns L, et al. Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for TNF-alpha (EULAR abstract THU0088). Ann Rheum Dis 2007;66(Suppl II):151.
-
(2007)
Ann Rheum Dis
, vol.66
, Issue.SUPPL. II
, pp. 151
-
-
Shealy, D.1
Cai, A.2
Lacy, E.3
Nesspor, T.4
Staquet, K.5
Johns, L.6
-
17
-
-
42449157502
-
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study
-
DOI 10.1002/art.23383
-
Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-975 (Pubitemid 351563997)
-
(2008)
Arthritis and Rheumatism
, vol.58
, Issue.4
, pp. 964-975
-
-
Kay, J.1
Matteson, E.L.2
Dasgupta, B.3
Nash, P.4
Durez, P.5
Hall, S.6
Hsia, E.C.7
Han, J.8
Wagner, C.9
Xu, Z.10
Visvanathan, S.11
Rahman, M.U.12
-
18
-
-
0023945481
-
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
-
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
-
(1988)
Arthritis Rheum
, vol.31
, pp. 315-324
-
-
Arnett, F.C.1
Edworthy, S.M.2
Bloch, D.A.3
McShane, D.J.4
Fries, J.F.5
Cooper, N.S.6
-
19
-
-
0029044362
-
Preliminary definition of improvement in rheumatoid arthritis
-
American College of Rheumatology
-
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-735
-
(1995)
Arthritis Rheum
, vol.38
, pp. 727-735
-
-
Felson, D.T.1
Anderson, J.J.2
Boers, M.3
Bombardier, C.4
Furst, D.5
Goldsmith, C.6
-
20
-
-
20744451898
-
Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: Argument in favor
-
DOI 10.1002/art.21243
-
Siegel JN, Zhen BG. Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor. Arthritis Rheum 2005;52:1637-1641 (Pubitemid 40852869)
-
(2005)
Arthritis and Rheumatism
, vol.52
, Issue.6
, pp. 1637-1641
-
-
Siegel, J.N.1
Zhen, B.-G.2
-
21
-
-
0028815803
-
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
-
Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
-
(1995)
Arthritis Rheum
, vol.38
, pp. 44-48
-
-
Prevoo, M.L.1
Van't Hof, M.A.2
Kuper, H.H.3
Van Leeuwen, M.A.4
Van De Putte, L.B.5
Van Riel, P.L.6
-
22
-
-
0003483167
-
-
Alphen Aan Den Rijn, The Netherlands: Van Zuiden Communications, BV
-
van Riel PL, van Gestel AM, Scott DL. EULAR handbook of clinical assessments in rheumatoid arthritis. Alphen Aan Den Rijn, The Netherlands: Van Zuiden Communications, BV, 2000.
-
(2000)
EULAR Handbook of Clinical Assessments in Rheumatoid Arthritis
-
-
Van Riel, P.L.1
Van Gestel, A.M.2
Scott, D.L.3
-
23
-
-
0018882143
-
Measurement of patient outcome in arthritis
-
DOI 10.1002/art.1780230202
-
Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-145 (Pubitemid 10164318)
-
(1980)
Arthritis and Rheumatism
, vol.23
, Issue.2
, pp. 137-145
-
-
Fries, J.F.1
Spitz, P.2
Kraines, R.G.3
Holman, H.R.4
-
24
-
-
0027412974
-
Minimum important difference between patients with rheumatoid arthritis: The patients perspective
-
Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-560 (Pubitemid 23102493)
-
(1993)
Journal of Rheumatology
, vol.20
, Issue.3
, pp. 557-560
-
-
Wells, G.A.1
Tugwell, P.2
Kraag, G.R.3
Baker, P.R.A.4
Groh, J.5
Redelmeier, D.A.6
-
25
-
-
34347267600
-
Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
-
DOI 10.1136/ard.2006.065615
-
Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-926 (Pubitemid 46999794)
-
(2007)
Annals of the Rheumatic Diseases
, vol.66
, Issue.7
, pp. 921-926
-
-
Bartelds, G.M.1
Wijbrandts, C.A.2
Nurmohamed, M.T.3
Stapel, S.4
Lems, W.F.5
Aarden, L.6
Dijkmans, B.A.C.7
Tak, P.P.8
Wolbink, G.J.9
-
26
-
-
33745291091
-
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial
-
Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-876 (Pubitemid 46768126)
-
(2006)
Annals of Internal Medicine
, vol.144
, Issue.12
, pp. 865-876
-
-
Kremer, J.M.1
Genant, H.K.2
Moreland, L.W.3
Russell, A.S.4
Emery, P.5
Abud-Mendoza, C.6
Szechinski, J.7
Li, T.8
Ge, Z.9
Becker, J.-C.10
Westhovens, R.11
-
27
-
-
34548757514
-
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice
-
DOI 10.1136/ard.2007.072447
-
Kievit W, Fransen J, Oerlemans AJM, Kuper HH, van der Laar MAFJ, de Rooij DJRAM, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007;66:1473-1478 (Pubitemid 350032655)
-
(2007)
Annals of the Rheumatic Diseases
, vol.66
, Issue.11
, pp. 1473-1478
-
-
Kievit, W.1
Fransen, J.2
Oerlemans, A.J.M.3
Kuper, H.H.4
Van Der Laar, M.A.F.J.5
De Rooij, D.J.R.A.M.6
De Gendt, C.M.A.7
Ronday, K.H.8
Jansen, T.L.9
Van Oijen, P.C.M.10
Brus, H.L.M.11
Adang, E.M.12
Van Riel, P.L.C.M.13
-
28
-
-
33750938687
-
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trials
-
DOI 10.1002/art.22193
-
Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006;54:3399-3407 (Pubitemid 44737150)
-
(2006)
Arthritis and Rheumatism
, vol.54
, Issue.11
, pp. 3399-3407
-
-
Zink, A.1
Strangfeld, A.2
Schneider, M.3
Herzer, P.4
Hierse, F.5
Stoyanova-Scholz, M.6
Wassenberg, S.7
Kapelle, A.8
Listing, J.9
-
29
-
-
46849110633
-
Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry
-
DOI 10.1136/ard.2007.087262
-
Hetland ML, Lindegaard HM, Hansen A, Podenphant J, Unkerskov J, Ringsdal VS, et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biologics affect treatment response and adherence to therapy? Results from the nationwide Danish Danbio Registry. Ann Rheum Dis 2008;67:1023-1026 (Pubitemid 351956667)
-
(2008)
Annals of the Rheumatic Diseases
, vol.67
, Issue.7
, pp. 1023-1026
-
-
Hetland, M.L.1
Lindegaard, H.M.2
Hansen, A.3
Podenphant, J.4
Unkerskov, J.5
Ringsdal, V.S.6
Ostergaard, M.7
Tarp, U.8
-
30
-
-
11144355274
-
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
-
DOI 10.1136/ard.2003.013052
-
van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-516 (Pubitemid 38530193)
-
(2004)
Annals of the Rheumatic Diseases
, vol.63
, Issue.5
, pp. 508-516
-
-
Van De Putte, L.B.A.1
Atkins, C.2
Malaise, M.3
Sany, J.4
Russell, A.S.5
Van Riel, P.L.C.M.6
Settas, L.7
Bijlsma, J.W.8
Todesco, S.9
Dougados, M.10
Nash, P.11
Emery, P.12
Walter, N.13
Kaul, M.14
Fischkoff, S.15
Kupper, H.16
|